Quoin Pharmaceuticals (QNRX) Q3 2025 earnings summary

Executive summary

• Advanced QRX003 in late-stage clinical trials for Netherton Syndrome and Peeling Skin Syndrome, with pivotal trial enrollment for Netherton Syndrome set for Q4 2025 and expanded pediatric program following positive safety and efficacy data.

• No commercialized products or revenue to date; operations funded through equity and debt financings.

• Closed private placement financing in October 2025, potentially raising up to $105.3 million to fund operations and R&D.

• Appointed Sally Lawlor as CFO to support commercialization and financial operations.

• Launched NETHERTON NOW awareness campaign, surpassing 1.5 million video views in six months.

Financial highlights

• Net loss for Q3 2025 was $3.95 million, up from $2.35 million in Q3 2024; nine-month net loss was $11.5 million, up from $6.7 million year-over-year.

• Operating expenses for Q3 2025 were $4.02 million, up 59% year-over-year, driven by increased R&D and G&A costs.

• Cash, cash equivalents, and marketable securities totaled $5.4 million as of September 30, 2025.

• Accumulated deficit reached $66.6 million at September 30, 2025.

• Total assets as of September 30, 2025: $6.4 million; total liabilities: $7.6 million.

Outlook and guidance

• Management expects continued significant R&D expenses as late-stage clinical trials progress and regulatory submissions are prepared.

• Current cash and recent financing expected to support operations into 2027.

• Additional financing will be required to fund operations until commercial profitability is achieved, which is not expected in the near term.

• Proceeds from private placement to fund operating expenses, R&D, clinical development, working capital, and potential acquisitions.

• Enrollment for QRX003 pivotal studies for Netherton Syndrome to begin in Q4 2025.